实验室单品
laboratory item
相关产品
CAS:1246814-57-2|Pamapimod-d4
- 产品货号:DT2025062122
- 发布时间:2025-06-09
- 产品CAS :1246814-57-2
- 产品规格:mg(更多包装需求请咨询客服)
- 产品纯度:≥98%
- 产品货期:现货下单后48小时内发货,定制产品4-8周。
- 运输条件:顺丰常规运输
产品详情
货号:DT2025062122
CAS:1246814-57-2
规格:mg(更多包装需求请咨询客服)
纯度:≥98%
生产商:试剂家
生物活性:Pamapimod-d4 (Ro4402257-d4) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment[1][2].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Pamapimod-d4 相关抗体:
p38 Antibody
Phospho-p38 (Thr180/Tyr182) Antibody
ASK1 Antibody (YA609)
MAPK14 Antibody
ATF2 Antibody
p38 Antibody (YA696)
Phospho-ATF2 (Thr71) Antibody
Phospho-MSK1 (Ser360) Antibody
p38 MAPK Antibody
GADD45A Antibody (YA1076)
RRAS Antibody (YA3212)
MAPKAP Kinase 2 Antibody
Phospho-MSK1 (Ser376) Antibody
MAP2K6 Antibody (YA1088)
p40 Antibody (YA1500)
PCPTP1 Antibody (YA1549)
Sprouty 2 Antibody (YA1604)
Sprouty 4 Antibody (YA1780)
MAPKAP Kinase 3 Antibody (YA3070)
MAPK6 Antibody (YA3194)
分子量:410.41
Formula:C19H16D4F2N4O4
CAS 号:1246814-57-2
非标记 CAS:449811-01-2
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (530 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[Content Brief]
[2]. Hill, R. J. et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. The Journal of pharmacology and experimental therapeutics 327, 610-619, doi:10.1124/jpet.108.139006 (2008).
[Content Brief]
在线留言
欢迎您访问“试剂家 | 纳米靶向科研平台”官方网站,请留下您的需求,我们会派专业人员及时与您联系,并为您提供相应的产品方案。